> ## Content Index
> Fetch the complete content index at: https://www.pennystocks.news/llms.txt
> Use this file to discover other available public pages before exploring further.

# NeOnc Technologies shares climb after Phase 2a brain-cancer trial results
- URL: https://www.pennystocks.news/nthi-neonc-technologies-shares-climb-after-phase-2a-brain-ca/
- Published: 2026-08-17T23:42:36.000Z
- Updated: 2026-08-25T01:39:18.000Z
- Description: NeOnc Technologies Holdings shares closed at $4.91, up 16.35% from a previous close of $4.22 on August 17, after Phase 2a results for its lead drug candidate circulated alongside several pieces of investor-relations content. Dollar volume was $1,716,903 across 3,469 trades. The
- Author: PennyStocksNews Team
- Tags: nasdaq, ticker-nthi

NeOnc Technologies Holdings shares **closed at $4.91, up 16.35%** from a previous close of $4.22 on August 17, after Phase 2a results for its lead drug candidate circulated alongside several pieces of investor-relations content. Dollar volume was $1,716,903 across 3,469 trades. The free float stands at 10,520,556 shares, representing 40.6% of shares outstanding. Short volume on the session was 78,713 shares, or 40.95% of reported volume.

Two of the three items in circulation originate from 24/7 Market News, which discloses in both releases that it **is compensated by NTHI** for ongoing news coverage and market outreach services. A third piece comes from Stonegate Capital Partners, an investor relations and capital markets advisory firm. All three should be read as attributed company-side material rather than independent analysis.

NeOnc Technologies Holdings, Inc. NASDAQ: NTHI 

The clinical data come from the company's own reporting. NEO100 is an intranasally administered formulation of purified perillyl alcohol, studied in recurrent IDH1-mutant high-grade glioma — a brain cancer in which the IDH1 gene carries a specific mutation. The trial's primary result was a **six-month progression-free survival rate of 48.9%**, measured against a pre-specified historical benchmark of 20%, with a reported p-value of 0.0047\. Progression-free survival tracks the proportion of patients whose cancer has not advanced and who have not died by a set point in time.

Median overall survival was reported at approximately 26.09 months. Six-, 12- and 24-month overall survival rates were approximately 86.7%, 60.9% and 54.1%, respectively. Five of 24 patients remained on treatment at the time of reporting, including one who had been progression-free for approximately 19 months. No major toxicities were reported.

The study was open-label and single-arm, with no randomised control group. Stonegate notes that **confirmation in a randomised study remains the next test**. Comparison against a historical benchmark carries inherent limitations that a randomised design would address.

The company says it intends to request a **Type B FDA meeting** to discuss the design of a registrational trial. NEO100 holds FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations. A second candidate, NEO212, has completed Phase 1 dose escalation at a recommended Phase 2 dose of 610 mg, according to the company's filings, and has received FDA feedback indicating a potential accelerated approval pathway, according to Stonegate.

On financing, the company has an at-the-market programme — a facility that allows it to sell shares into the open market incrementally over time — authorising up to $75 million of common stock through BTIG and A.G.P./Alliance Global Partners. The company has stated this is a financing facility, not cash already on hand. The company's SEC filings describe a USC patent portfolio covering **28 issued and 14 pending U.S. patents**, plus 65 issued and 28 pending internationally, across NEO100, NEO212 and related programmes.

Second-quarter R&D expense was reported at **approximately $2.6 million**, compared with approximately $0.7 million in the same period a year earlier, reflecting increased clinical activity, manufacturing and development work, according to the company.